Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palatability of Eliglustat Liquid Formulations
NCT02422654Phase 1Completed
- Sponsor
- Sanofi
- Start
- Apr 2015
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of eliglustat in Gaucher disease (GD) (15 arms), sponsored by Sanofi. Primary endpoint: Measurement of palatability by 100 mm visual analogue scale (VAS) for overall acceptability. Started Apr 2015; status: completed.
02
Drugs
eliglustat
03
Conditions
Gaucher disease (GD)
Beyond the preview
Go deeper on NCT02422654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02422654.